Latest Growth hormone treatment Stories
NES-ZIONA, Israel, May 7, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH) today reported top-line results from a Phase II four-month treatment extension study of hGH-CTP, its long-acting version of human growth hormone, in growth hormone deficient adults. The data reaffirms the company's prior Phase II findings showing that a single weekly injection of hGH-CTP has the potential to replace seven consecutive daily injections of currently marketed human growth hormone...
PRINCETON, N.J., April 26, 2012 /PRNewswire/ -- Novo Nordisk Inc. (NYSE: NVO), a global healthcare company with 89 years of innovation and leadership in diabetes care, was named as one of the "Best Places to Work in New Jersey" by NJBIZ, the state's largest weekly business journal. This is the eighth time Novo Nordisk has appeared on the annual list. Earlier this year, Novo Nordisk was recognized for the fourth straight year as one of FORTUNE Magazine's "100 Best Companies to Work...
NES-ZIONA, Israel, April 17, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH) today reported positive preclinical results from an animal study of its long-acting obesity/Type II diabetes drug candidate MOD-6030. The study was designed to measure the potential therapeutic effect of MOD-6030 injected once weekly as measured by weight loss, reduction in food intake, glycemic control and cholesterol levels. The study results will be presented at GTC's 5th Diabetes Drug...
By Fernanda Barros, Ivanhoe Health Correspondent (Ivanhoe Newswire) -- It is rapidly becoming the number one health problem in the U.S. and it is now the most common chronic illness in childhood. Obesity is a complex and potentially devastating condition, particularly if its onset is in early childhood. There are significant environmental and behavioral factors involved in the causes of obesity but some of us may carry it in our genes! In the most recent National Health and Nutrition...
NES-ZIONA, Israel, March 20, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in children with growth hormone deficiency. The pediatric trial follows successful completion of a Phase II trial of hGH-CTP in growth hormone deficient adults, which demonstrated that hGH-CTP was...
Trial conducted through a Cooperative Research and Development Agreement QUÉBEC CITY, March 8, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the Michael E. DeBakey Veterans Affairs Medical Center, in Houston, Texas, has initiated a Phase 2A trial assessing the safety and efficacy of repeated doses of the Company's ghrelin agonist, AEZS-130 (macimorelin), in patients with cancer cachexia. The study is conducted under...
FLINT, Mich., March 1, 2012 /PRNewswire/ -- In an effort to put Chicago on the map as the healthiest city in the United States, Diplomat Specialty Pharmacy, the nation's largest privately held specialty pharmacy offering bioidentical hormone therapy, and Ageology anti-aging physician network have formed a strategic alliance. The two companies focus on delivering holistic preventative care to men and women looking to fight chronic diseases with nutrition, fitness and bioidentical...
PRINCETON, N.J., Jan. 19, 2012 /PRNewswire/ -- Novo Nordisk (NYSE: NVO), the world leader in diabetes care, has been ranked 43rd in FORTUNE magazine's 2012 "100 Best Companies to Work For" list. Reflecting the passion of Novo Nordisk's employees, the company has been highlighted on the list for four consecutive years. (Logo: http://photos.prnewswire.com/prnh/20110414/NY80976LOGO ) "I'm convinced that it is our people who set us apart. Each and every person at Novo Nordisk...
NES-ZIONA, Israel, Jan. 18, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH) today announced positive top-line results from a post-Phase II clinical study of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in growth hormone deficient adults. The data show that two injections of hGH-CTP per month have the potential to replace 30 consecutive daily injections of currently marketed human growth hormone. "We believe that the findings from this...
QUÉBEC CITY, Nov. 28, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the U.S. Food and Drug Administration (FDA) has granted Jose M. Garcia, MD, PhD, Assistant Professor, Division of Diabetes Endocrinology and Metabolism, Departments of Medicine and Molecular and Cell Biology, Baylor College of Medicine and Michael I. DeBakey Veterans Administration Medical Center, in Houston Texas, an Investigational New Drug (IND)...
